The members section of the ISH website is currently being upgraded.

We apologise that you cannot access it at present but we will be back online shortly.
In the meantime, please call the Secretariat with any questions on +44 (0) 20 8977 7997

International Society of Hypertension

ISH - Hero Image 1ISH - Hero Image 2ISH - Hero Image 3ISH - Hero Image 5ISH - Hero Image 6ISH - Hero Image 7ISH - Hero Image 8ISH - Hero Image 9ISH - Hero Image 10ISH - Hero Image 11ISH - Hero Image 12ISH - Hero Image 13ISH - Hero Image 14ISH - Hero Image 15ISH - Hero Image 16ISH - Hero Image 17

About Our Corporate Members

The ISH Council would like to acknowledge the assistance of the following Corporate Members who are participating in the ISH and therefore helping to promote the advancement of scientific research and knowledge in hypertension and associated cardiovascular diseases.

Current Corporate Member

  • Astellas

    Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 16,000 employees worldwide.

    more

    The organization is committed to becoming a global category leader in Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience, DM Complications and Metabolic Diseases.

    Astellas has a number of key strengths in the Japanese market: one of the largest teams of quality MRs with high-level detailing skills; a rich lineup of products, both in terms of therapeutic areas and numbers of products; and solid promotional and support system capable of marketing numerous products at the same time. Astellas can also point to several successful marketing alliances for major products including a treatment for hypertension. For more information on Astellas Pharma Inc.

    For more information please visit astellas.com/en

  • Daiichi Sankyo

    Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.

    more

    While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain.

    For more information, please visit: daiichisankyo.com.

  • Mitsubishi Tanabe

  • Omron

  • Servier

  • Takeda

Companies wishing to become Corporate Members of the ISH should contact the Secretariat for further details.